Hims & Hers Health: Q2 2026 Earnings

Four things shaped the print. Three point toward genuine strength; one, the branded GLP-1 mix shift, is the same driver behind both this quarter's biggest positive and its biggest problem.

What happened: International revenue grew roughly 17-fold YoY to $131.4M after the Eucalyptus acquisition closed in June, adding reach across the UK, Canada, Germany, Ireland, France, and Spain.

Why it matters: This is mostly an acquisition-driven step change, not organic growth. The real test starts now: whether HIMS can grow that acquired base rather than just having added it.

What happened: Monthly revenue per average subscriber rose to $92 from $76 a year ago, as HIMS's strategic shift toward branded GLP-1 medications, with compounded versions offered only "on a limited scale," pushed more subscribers onto higher-priced products.

Why it matters: Higher revenue per subscriber looks like pricing power. It came bundled with a much higher cost of goods, which is exactly why gross margin moved in the opposite direction; see Section 04 below.

What happened: U.S. revenue grew 16% YoY to $621.8M, and management said domestic growth accelerated during the quarter and is expected to keep accelerating through the second half.

Why it matters: After a softer Q1, this is evidence the core U.S. subscriber business isn't stalling, it's simply growing more slowly than the acquisition-boosted international segment.

What happened: Management raised FY26 revenue guidance to $3.1B–$3.3B from $2.8B–$3.0B, roughly a 10% increase at the midpoint.

Why it matters: A raise this size signals real confidence in the growth trajectory, but the EBITDA side of that same guidance moved in a notably less confident direction (Section 08).

HIMS doesn't have a growth problem this quarter. Revenue, subscribers, and guidance are all up. The problem is what's happening beneath the top line: gross margin fell 12 points, and adjusted EBITDA, the metric most closely tied to underlying profitability, actually shrank year over year, despite beating Wall Street's estimate. A number can beat a lowered bar and still be getting worse; that's what happened here.

Company-reported, GAAP gross margin and non-GAAP adjusted EBITDA

Operating and net results absorbed both the margin compression and one-time items. Operating loss was $(97.2)M versus operating income of $26.7M a year ago; net loss was $(86.3)M versus net income of $42.5M. Six-month restructuring charges tied to the GLP-1 shift totaled $38.1M, and six-month legal contingency charges reached $62.5M (more on both in Section 06).

It's worth stating plainly, because the two metrics point in opposite directions: revenue per subscriber rose 21% year over year while gross margin fell 12 points over the same period. Both are consequences of the same branded-GLP-1 pivot: the product got more expensive to buy and more expensive to sell.

For investors, the takeaway isn't that one number is "real" and the other is "fake." Both are accurate. It's that ARPU growth driven by a costlier product mix is a weaker quality of growth than ARPU growth driven by pure pricing power or upsell, because it doesn't automatically convert into more profit per subscriber. Whether HIMS can narrow that gap, through better wholesale terms, scale, or a more favorable branded/compounded mix, is the single most important unit-economics question in this report.

International (Rest of World) revenue reached $131.4M, up roughly 17-fold YoY, following the June close of the Eucalyptus acquisition, expanding HIMS's footprint into the UK, Canada, Germany, Ireland, France, and Spain, among other markets.

Management has previously pointed to a longer-term ambition of $1 billion-plus in international revenue; this quarter's jump is a real structural step in that direction, but it is overwhelmingly acquisition-driven rather than organic. The purchase price for Eucalyptus was not disclosed in the earnings release. What matters from here is the organic growth rate of the combined international base once the acquisition's one-time step change laps itself.

HIMS holds roughly $841M of cash and short-term investments against $1.37 billion of convertible debt and just $324.1M of total stockholders' equity: convertible notes run more than four times the size of the equity base. That's not an immediate solvency concern given the cash on hand, but it is a capital-structure fact worth tracking: a heavier reliance on convertible debt than the original document suggested, with real dilution risk if the notes convert and refinancing risk whenever they eventually mature.

The $250M buyback program, authorized in November 2025, followed a prior $100M program that was fully utilized. We could not confirm from available disclosures how much of the new authorization has actually been repurchased through Q2. Buying back stock while burning free cash flow and carrying substantial convertible debt is a tension worth watching rather than a settled positive.

This is more tangled than a single "resolved dispute," and it's worth separating the threads:

• FTC lawsuit (active): The FTC, joined by Utah and California, sued HIMS in late July 2026, alleging unlawful sharing of consumer health data with advertising platforms and deceptive billing/cancellation practices. This is the freshest and least resolved of the three items.
• Novo Nordisk patent suit (resolved, then superseded): Novo Nordisk sued HIMS on February 9, 2026 over compounded copies of Wegovy; the stock fell sharply on the news. Novo Nordisk dropped the suit in March 2026, and the two companies announced a new collaboration the same month for HIMS to offer branded Wegovy, alongside HIMS's shift to a limited-scale compounded offering.
• Securities class action (ongoing): A separate shareholder suit alleges HIMS misrepresented the terms of its original 2025 Novo Nordisk partnership before its termination. The lead-plaintiff deadline passed in August 2025; the litigation itself remains open.

Six-month legal contingency charges reached $62.5M, recognized in G&A, on top of roughly $15M already booked in Q1, implying a meaningfully larger incremental charge in Q2 alone. Combined with the $38.1M of six-month restructuring costs tied to the GLP-1 shift, "one-time" items have now shown up in back-to-back quarters, which raises a fair question about how one-time they really are.

The revenue raise is straightforward. The EBITDA guidance tells a more cautious story once you look at both ends of the range.

Ceiling trimmed by $25M; floor unchanged, scaled to the prior guide's $350M ceiling

The floor of the EBITDA range held at $275M, but the ceiling was cut from $350M to $325M, even as the revenue guide rose by roughly $300M at the midpoint. Rough math: the prior guide implied about a 10.8% full-year EBITDA margin at the midpoint; the new guide implies closer to 9.4%. Management is effectively guiding to a lower-margin year than it was three months ago, even while guiding to more revenue.

For Q3 specifically, management guided to revenue of $880M–$900M (about 12% above consensus heading into the print) and adjusted EBITDA of $75M–$95M, implying a 9–11% margin, roughly in line with or slightly above Q2's 8% margin. That's a signal margin isn't guided to collapse further in the near term, but it's not a guided snap-back to last year's levels either.

• Branded GLP-1 sourcing costs decline as HIMS gains scale or negotiates better wholesale terms with manufacturers.
• The Eucalyptus integration drives operating leverage as shared infrastructure spreads across a larger international base.
• Legal and restructuring charges roll off as the FTC matter and remaining litigation are resolved.

• The FTC case produces a settlement or consent decree that imposes new compliance costs on data practices and billing.
• Further compounding-related disputes resurface as branded and compounded GLP-1s continue to coexist on the platform.
• The branded mix keeps growing faster than any offsetting cost efficiencies, pulling gross margin lower before it stabilizes.

• Gross margin: Does it stabilize near 64% in Q3, or keep sliding as the branded GLP-1 mix keeps growing?
• FTC litigation: Any settlement, consent decree, or escalation of the data-sharing and billing-practices case?
• EBITDA margin guide: Does management hold the trimmed FY26 range, or narrow it further as the year progresses?
• International organic growth: Stripping out Eucalyptus, is the international base actually growing, or was this a one-time step change?
• One-time charges: Do restructuring and legal contingency costs shrink in Q3, or recur again for a third straight quarter?

Next scheduled report: Q3 2026, expected November 9, 2026.

The quarter proved HIMS's growth engine is intact: revenue beat by a wide margin, subscribers grew 19%, international expansion took a real structural step forward, and management raised full-year revenue guidance by roughly 10%.

The key risk is quality of earnings. Gross margin fell 12 points, adjusted EBITDA declined year over year despite beating estimates, and management's own updated guidance quietly lowered its implied full-year margin even as it raised revenue. Layer on a genuinely tangled legal picture: an active FTC lawsuit, ongoing securities litigation, and two straight quarters of "one-time" restructuring and legal charges, and this reads less like a clean beat than the original headline suggested.

From here, the case turns on whether branded GLP-1 economics improve with scale and whether the FTC matter resolves without lasting cost, or whether 64% gross margin and a sub-9%-EBITDA-margin full year are simply the new shape of this business.

HIMS heads into the next print with a genuinely split picture: durable top-line growth on one side, a real deterioration in earnings quality on the other. Rather than calling a winner off the headline beat or miss, the framework below lays out what each side of that split would look like in practice, and what to watch for as it resolves.

In practice, the read is structural rather than fundamental. Watch how price reacts to this print and the next one: if pullbacks keep holding above the post-earnings low, that higher-low pattern lines up with the growth case reasserting itself, but if the stock keeps carving out lower lows into results, that's the market voting for the margin story instead. Either way, it's that price structure, not the next headline number on its own, that will actually confirm which case is playing out.

Click to enlarge

HIMS — Daily. Rising channel off the early-2026 low, with a buy-level reference near the 0.618 retracement, a target reference near $40, and the 1.618 extension near $65.73 marked for structural context. Illustrative only — not a specific entry, exit, or price target. Click the chart to enlarge.